Decreased lung cancer survival with hormone-replacement therapy: Caused by a decreased tissue factor pathway inhibitor level? [5]

Journal of Clinical Oncology

Volumn 24, Issue 17, 2006, Pages 2683-2684

  Negaard, Helene F S ^a   Eilertsen, Anette L ^a   Dahm, Anders ^a   Iversen, Per O ^a   Østenstad, Bjørn ^a   Sandset, Per M ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

BLOOD CLOTTING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HORMONE SUBSTITUTION; HUMAN; LETTER; LUNG SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; DRUG EFFECT; FEMALE; LUNG TUMOR; METABOLISM; MORTALITY; NOTE;

ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 33748172965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.4345     Document Type: Letter

References (8)

1. Ganti AK, Sahmoun AE, Panwalkar AW, et al: Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24:59-63, 2006
2. Siegfried JM: Hormone replacement therapy and decreased lung cancer survival. J Clin Oncol 24:9-10, 2006
3. Bladbjerg EM, Madsen JS, Kristensen SR, et al: Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: A randomized controlled study. J Thromb Haemost 1:1208-1214, 2003
4. Dahm A, Van Hylckama Vlieg A, Bendz B, et al: Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101:4387-4392, 2003
5. Mousa S, Mohamed S: Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaprin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 92:627-633, 2004
6. Amirkhosravi A, Meyer T, Chang JY, et al: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 87:930-936, 2002
7. Altinbas M, Coskun HS, Er O, et al: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266-1271, 2004
8. Sandset PM, Bendz B, Hansen JB: Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 30:48-56, 2000